Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials.
Authors
Mossop, Helen
Publication Date
2022-02Journal Title
Br J Cancer
ISSN
0007-0920
Publisher
Springer Science and Business Media LLC
Volume
126
Issue
2
Pages
204-210
Language
en
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Mossop, H., Grayling, M. J., Gallagher, F. A., Welsh, S. J., Stewart, G. D., & Wason, J. M. (2022). Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials.. Br J Cancer, 126 (2), 204-210. https://doi.org/10.1038/s41416-021-01613-5
Description
Funder: RCUK | MRC | Medical Research Foundation; doi: https://doi.org/10.13039/501100009187
Funder: NIHR Biomedical Research Centre BRC-1215-20014
Abstract
BACKGROUND: Efficient trial designs are required to prioritise promising drugs within Phase II trials. Adaptive designs are examples of such designs, but their efficiency is reduced if there is a delay in assessing patient responses to treatment. METHODS: Motivated by the WIRE trial in renal cell carcinoma (NCT03741426), we compare three trial approaches to testing multiple treatment arms: (1) single-arm trials in sequence with interim analyses; (2) a parallel multi-arm multi-stage trial and (3) the design used in WIRE, which we call the Multi-Arm Sequential Trial with Efficient Recruitment (MASTER) design. The MASTER design recruits patients to one arm at a time, pausing recruitment to an arm when it has recruited the required number for an interim analysis. We conduct a simulation study to compare how long the three different trial designs take to evaluate a number of new treatment arms. RESULTS: The parallel multi-arm multi-stage and the MASTER design are much more efficient than separate trials. The MASTER design provides extra efficiency when there is endpoint delay, or recruitment is very quick. CONCLUSIONS: We recommend the MASTER design as an efficient way of testing multiple promising cancer treatments in non-comparative Phase II trials.
Keywords
Article, /692/308/2779/109/2425, /692/308/2779/777, article
Sponsorship
Cancer Research UK Cambridge Centre [C9685/A25177]
Funder references
MRC (MR/T024097/1)
Cancer Research UK (C96/A25177)
National Institute for Health Research (IS-BRC-1215-20014)
Identifiers
s41416-021-01613-5, 1613
External DOI: https://doi.org/10.1038/s41416-021-01613-5
This record's URL: https://www.repository.cam.ac.uk/handle/1810/333168
Rights
Licence:
http://creativecommons.org/licenses/by/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.